Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a wide variety ...

Patients being treated for neovascular age-related macular degeneration (nAMD) appear to have less likelihood of submacular hemorrhage (SMH) when their most recent biologic agent was faricimab, ...

Bevacizumab (Avastin). This is a widely used and cost-effective drug for wet AMD injections. The FDA approved it to treat colon cancer in 2004. (It works by stopping the growth of new blood vessels.) ...

Avastin costs around £28 per injection when used off-label as an intravitreal injection for AMD, which compares to a cost of £816 for Eylea and £551 for Lucentis, according to the judicial ...

marketed as Avastin for the treatment of cancer, is not manufactured or licensed for use in the eye. A service using this product risks increasing the number of clinic visits and injections a ...

Meanwhile, caretaker Punjab Health Minister Dr Jamal Nasir has constituted a five-member committee to review the case of eye infection due to Avastin injection. Dr. Asad Aslam Khan of King Edward ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...

by Intravitreal Injection of Bevacizumab and Ranibizumab. † Theoretical mean number of injections per year based on monthly dosing regimen. Bs: Bevasiranib sodium; CABERNET: A study of Strontium ...

Thirty-four relevant articles were identified. Twelve described immediate or short-term IOP elevation, and 22 described long-term or sustained IOP elevation. Pertinent details of these ...

In an advisory released here on Monday, the DRAP said, “recently, adverse drug reactions (DARs) have been reported in a healthcare facility following the use of Avastin injections ...